Autres langues Actinogen Medical Limited

Actions

ACW

AU000000ACW3

Temps Différé Australian S.E. Autres places de cotation 04:16:23 14/05/2024			Varia. 5j.	Varia. 1 janv.
0,028 ^AUD	0,00%		-15,62%	+22,73%

03/05	Actinogen Medical lève jusqu'à 8,9 millions de dollars australiens pour l'avancement de l'essai et le fonds de roulement ; les actions chutent de 24%.	MT
22/04	Actinogen Medical Limited annonce le recrutement complet de 167 participants à l'essai clinique de phase 2A de la société XanaCIDD chez des patients souffrant de troubles cognitifs dans le cadre d'un trouble dépressif majeur	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer	07/05
Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	03/05
Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	22/04
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%	22/04
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial	15/04
Actinogen Doses First Patient in Phase 2b Alzheimer’s Disease Trial; Shares Rally 16%	15/04
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	25/03
Actinogen Medical Initiates Final Enrolment Phase for XanaCIDD Depression Trial; Shares Rise 3%	07/03
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	25/02
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment	15/02
Actinogen Medical Activates First Trial Site for Phase 2B Alzheimer’s Disease Trial	20/12
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial	28/11
Actinogen Medical's XanaCIDD Trial Enrolment Surpasses 50% Milestone	28/11
Actinogen Medical Receives AU$4.8 Million R&D Tax Refund	28/11
Actinogen Medical Names CFO	08/11
Actinogen Medical Limited Announces CFO Changes	07/11
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston	13/10/23
Actinogen Medical Redesigns Phase 2b Trial of Alzheimer's Disease Drug	27/09/23
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results	26/09/23
Actinogen Medical Completes AU$10 Rights Issue	07/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Actinogen Medical Limited

Actions

ACW

AU000000ACW3

Autres langues

Filtres